This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to adolescents (12- to 18-year-olds).
This document offers practical guidance for EU/EEA Member States on implementing genomic SARS-CoV-2 surveillance. It also includes advice on how to estimate the number of sequenced samples needed to achieve various objectives, including the early detection of novel variants.
Several SARS-CoV-2 variants have been identified. Some of these variants have mutations that (alone or in combination) may provide the virus with a selective advantage, such as increased transmissibility or the ability to evade the host immune response, or cause possible changes in pathogenicity, thus increasing disease severity.
This technical report provides a summary of the evidence available at the time of the publication and what will be required in the future to support EU/EEA countries taking decisions on administration of the second dose, following a first dose of Vaxzevria. Since new evidence is being generated continuously and safety monitored on an ongoing basis, it is essential for readers to consider the latest available information.
This document outlines the public health considerations for the use of rapid antigen detection tests (RADTs), including self-test RADTs to detect SARS-CoV-2 in individuals in occupational settings in the European Union/European Economic Area (EU/EEA), and provides information on the use of such tests in an occupational safety and health at work context.
This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.
This document aims to provide interim guidance on the risks for fully vaccinated individuals to develop or transmit
infection that will give rise to severe COVID-19 disease in the context of the current epidemiological and vaccine
coverage situation in the EU/EEA.
The aim of this document is to present the findings of a survey of EU/EEA countries carried out to ascertain
surveillance practices implemented to document and report suspected reinfection cases.